共 78 条
[1]
Murphy RL(2003)Reviving protease inhibitors: new data and more options J Acquir Immune Defic Syndr 33 S43-52
[2]
Raffi F(2003)Releasing the true power of protease inhibitors Int J STD AIDS 14 29-33
[3]
Goldsmith DR(2003)Atazanavir Drugs 63 1679-93
[4]
Perry CM(2000)BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents Antimicrob Agents Chemother 44 2093-9
[5]
Robinson BS(2001)Hollow-fibre unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable J Infect Dis 183 1126-9
[6]
Riccardi KA(2000) resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632 Antimicrob Agents Chemother 44 2319-26
[7]
Gong Y(2004)Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens J Infect Dis 189 1802-10
[8]
Drusano GL(2003)Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors Antimicrob Agents Chemother 47 1324-33
[9]
Bilello JA(2003)Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples [letter] AIDS 17 1258-61
[10]
Preston SL(2005)Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures AIDS 19 685-94